SL1703 / Beijing GoBroad Hospital, SenlangBio - LARVOL DELTA

A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure (ASH 2025) - P1 | "Two patients relapsed and died at 6 months, while the others remained remission. Conclusion The novel tandem bispecific nanobody-based CD19/BCMA CAR-T cell therapy might rescue the failure ofprevious BCMA CAR-T therapy.The phase 1 clinical trial has been registered and isrecruiting(NCT07003555)."

Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients (ASH 2025) - P1/2 | "Their persistent killing capacity against CD19+ or BCMA+ targets was comparable to that of singleCD19 or BCMA CAR-T cells. Novel Loop dual CD19/BCMA CAR-T demonstrated favorable efficacy and safety inrelapsed/refractory autoimmune diseases and new clinical trial is ongoing (NCT06947460)."

Clinical • IO biomarker • Cardiovascular • Fibrosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

Big Announcement | Senlang Biotechnology’s 6 Cutting-Edge Achievements to be Showcased at ASH2025 [Google translation] (Senlang Biotech Press Release) - "The company will officially release six of its latest clinical research findings during the conference, including its core products: CD7-targeted SENL101, CD19/BCMA dual-targeted SL1703, CD19/CD20 dual-targeted SL1716, and BCMA/GPRC5D dual-targeted SL0439."

Clinical data • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (clinicaltrials.gov) - P1/2 | N=45 | Not yet recruiting | Sponsor: Beijing GoBroad Hospital | Initiation date: May 2025 ➔ Sep 2025

Trial initiation date • Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis